EMA Authorised: Tivdak (tisotumab vedotin) — Genmab A/S

View source ↗

Summary

EMA authorised Tivdak (tisotumab vedotin) for uterine cervical neoplasms, expanding treatment options in this indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Cervical Neoplasms

Drugs mentioned

• TIVDAK (tisotumab vedotin)

Snippet

Status: Authorised. Therapeutic area: Uterine Cervical Neoplasms. MAH: Genmab A/S. Decision date: 02/06/2026